HK Stock Market Move | MARKETINGFORCE(02556) closes up nearly 10%, full stack Token factory opens up new space for AI applications
Mai Fu Shi (02556) closed up nearly 10%, with a 9.84% increase at the close, reaching 37.3 Hong Kong dollars, with a trading volume of 178 million Hong Kong dollars.
MARKETINGFORCE (02556) rose nearly 10%, closing up 9.84% at 37.3 Hong Kong dollars, with a trading volume of 1.78 billion Hong Kong dollars.
On the news front, MARKETINGFORCE raised nearly 500 million Hong Kong dollars through a targeted placement today, strengthening its intelligent computing infrastructure and collaborating with Muxi to introduce domestic GPU computing power support, further enriching the source of underlying computing power. Huatai believes that the full-stack Token Factory is expected to enhance the company's AI application delivery capabilities and drive the expansion of fee models towards volume-based and performance-based directions.
The firm pointed out that the company's moat lies in the customer data, business processes, industry knowledge graph, and system connectivity capabilities formed through long-term cultivation of marketing and sales scenes. Enterprise-level AI applications require support for scene and business closed loops. The company will transform industry experience into scene capabilities and provide scene delivery through the full-stack Token Factory, aiming to further strengthen the efficiency of AI application delivery and open up long-term growth space.
Related Articles

RONGTA TECH (09881) suggests the removal of Luo Bingxian Yongdao from the position of company auditor.

SIMCERE PHARMA (02096): SIM0689 (PD-1/VEGF dual-specific antibody) has obtained the drug clinical trial approval notice issued by the National Medical Products Administration.

SEACON (02409) subsidiary enters into a vessel time charter arrangement with Zhejiang Shipping (Singapore)
RONGTA TECH (09881) suggests the removal of Luo Bingxian Yongdao from the position of company auditor.

SIMCERE PHARMA (02096): SIM0689 (PD-1/VEGF dual-specific antibody) has obtained the drug clinical trial approval notice issued by the National Medical Products Administration.

SEACON (02409) subsidiary enters into a vessel time charter arrangement with Zhejiang Shipping (Singapore)

RECOMMEND





